Brought to you by 
Novartis gets global license to Portola's elinogrel; terminated
19 Apr 2021
Executive Summary
Portola Pharmaceuticals (developing new therapeutics for cardiovascular disease, inflammatory disease, and cancer) licensed Novartis exclusive worldwide rights to develop and commercialize its Phase II cardiovascular compound elinogrel (PRT060128).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis gets global license to Portola's elinogrel; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice